Jefferies raised the price target for the Inozyme Pharma Inc (NASDAQ:INZY) stock from “a Hold” to “a Buy”. The rating was released on March 23, 2023, according to finviz. The research report from H.C. Wainwright has initiated the stock to Buy, with a price target set at $33. The stock was initiated by Needham, who disclosed in a research note on November 29, 2021, to Buy and set the price objective to $23. In their research brief published August 18, 2020, Wedbush analysts initiated the Inozyme Pharma Inc stock to Outperform with a price target of $35.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.33 during the last quarter as opposed to a consensus estimate of -$0.32, which indicates the company missed its estimate by -$0.01, which implies that the company surprised the market by -3.10%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is -$0.36. This is an average of 6 analysts’ earnings, where the high earnings per share estimate is -$0.3 and the low earnings per share estimate is -$0.39.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 30.49% within the last five trades and 16.77% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 69.47% in the last 6 months and 70.22% was added to its value over the previous 3 months. INZY stock is trading at a margin of 25.17%, 35.12% and 61.08% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, INZY deals in the Healthcare domain. The stock is trading 1.32 percent below its 52-week high and 184.86 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 63.6. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Inozyme Pharma Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $473.16 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 3.37, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 33.38 percent of Inozyme Pharma Inc shares are owned by insiders, and 60.15 percent are held by financial institutions. Hopfner Robert Lorne, the Director at Inozyme Pharma Inc (INZY) has bought 833,333 shares of firm on Aug 01 ’23 at a price of $4.80 against the total amount of $4.0 million. In another inside trade, Pivotal bioVenture Partners Fu, Director of Inozyme Pharma Inc (NASDAQ:INZY) bought 833,333 shares of the firm on Aug 01 ’23 for a total worth of $4.0 million at a price of $4.80. An inside trade which took place on May 12 ’23, Director of Inozyme Pharma Inc Hopfner Robert Lorne bought 228,702 shares of firm against total price of $1.43 million at the cost of $6.25 per share.
